Neuraltus ALS drug wins fast track, orphan status - San Francisco Business Times
**** "An experimental treatment for Lou Gehrig’s disease won fast track and orphan drug designations from the Food and Drug Administration, potentially speeding ..."
Kickstarter film project, ALS patients face life-and-death deadlines - San Francisco Business Times
"Neuraltus won't release data from the Phase II trial of NP-001 until later this year, possibly next month. The drug last summer won Food and Drug Administration fast-track and orphan drug designations, which potentially could accelerate the clinical trial process by waiving FDA fees and providing tax breaks for the company's clinical trial costs."
Orphan designation of sodium chlorite, EU/3/13/1139 - European Medicines Agency
"On 19 June 2013, orphan designation (EU/3/13/1139) was granted by the European Commission to Shore Limited, United Kingdom, for sodium chlorite (also known as NP001) for the treatment of amyotrophic lateral sclerosis." {Other listed sponsor: FGK Representative Services GmbH, Germany}